Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization

Table 5 Statistical comparison of pertinent clinical parameters between subtype V patients treated with and without adjuvant chemotherapy.

	Molecular Subtype V Breast Cancer
	Adjuvant Rx		No-Adjuvant Rx		pvalues*
	Patient (n = 28)		Patient (n = 12)
Age at diagnosis
< 50 yr	16	57.1%	5	41.7%	0.49
>= 50 yr	12	42.9%	7	58.3%
TNM Path T
1	14	50.0%	8	66.7%	0.14
2	14	50.0%	3	25.0%
3	0	0.0%	0	0.0%
4	0	0.0%	1	8.3%
TNM Path N
0	13	46.4%	7	58.3%	0.86
1	8	28.6%	4	33.3%
2	5	17.9%	1	8.3%
3	2	7.1%	0	0.0%
TNM Path M
0	28	100.0%	12	100.0%
Positive Lymph Nodes
0	13	46.4%	7	58.3%	0.86
1-3	8	28.6%	4	33.3%
4-9	5	17.9%	1	8.3%
> = 10	2	7.1%	0	0.0%
TNM Stage
I	7	25.0%	6	50.0%	0.34
II	14	50.0%	4	33.3%
III	7	25.0%	2	16.7%
Nuclear Grade
1	4	14.3%	5	41.7%	0.17
2	13	46.4%	4	33.3%
3	8	28.6%	2	16.7%
Hormonal Therapy
No	3	10.7%	2	16.7%	0.63
Yes	25	89.3%	10	83.3%
Post-op Radiation Rx
No	20	71.4%	9	75.0%	1.00
Yes	8	28.6%	3	25.0%

*: p values were determined by Fisher's exact test
There was no difference in follow-up duration between two groups (median 10.4 vs. 9.2 years, p = 0.17 by Wilcoxon rank sum test)

ISSN: 1471-2407